After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Abstract: This paper proposes an innovative recursive filtering algorithm for nonlinear microseismic systems with signal attenuation. Firstly, the microseismic wavelet and nearby noise are modeled as ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Recursion Pharmaceuticals' stock jumped after the FDA announced plans to replace the use of animals in drug testing. Recursion is a leader in AI-powered drug discovery and development. It remains to ...

The last time I wrote about Recursion Pharmaceuticals (RXRX) it was with respect to a Seeking Alpha article entitled "Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245". In ...

Recursion Pharmaceuticals has a flashy drug development platform. It has a lot to prove about whether that platform's use of AI is helpful. Some power players have backed it with significant ...

Abstract: In recent years, the spotlight of research in the adaptive learning era has turned toward distributed adaptive filtering algorithms for sparse systems over ...